What's Happening?
Oramed Pharmaceuticals Inc. has announced its inclusion in the U.S. small-cap Russell 2000 and broad-market Russell 3000 Indexes following the 2026 Russell indexes semi-annual reconstitution. This inclusion will be effective after the close of U.S. markets
on June 26, 2026, and will be reflected in trading from June 29, 2026. The Russell indexes are widely used by investment managers and institutional investors for benchmarking and active investment strategies, with approximately $12.2 trillion in assets benchmarked against them.
Why It's Important?
Joining the Russell 2000 and Russell 3000 Indexes is a significant milestone for Oramed Pharmaceuticals, as it enhances the company's visibility and credibility in the investment community. This inclusion can attract more institutional investors and potentially increase the company's stock liquidity and valuation. It reflects Oramed's growth and market capitalization, positioning it as a notable player in the pharmaceutical industry. The move could lead to increased investor interest and support the company's future growth and strategic initiatives.
